Tofacitinib for the Treatment of Pyoderma Gangrenosum.

Adult Female Histocytochemistry Humans Immunohistochemistry Immunologic Factors / administration & dosage Male Middle Aged Piperidines / administration & dosage Protein Kinase Inhibitors / administration & dosage Pyoderma Gangrenosum / drug therapy Pyrimidines / administration & dosage Pyrroles / administration & dosage Skin / pathology Treatment Outcome Young Adult

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
04 2019
Historique:
received: 08 09 2018
revised: 23 10 2018
accepted: 26 10 2018
pubmed: 8 11 2018
medline: 30 7 2020
entrez: 8 11 2018
Statut: ppublish

Résumé

Pyoderma gangrenosum (PG) is a difficult-to-treat inflammatory skin condition that affects inflammatory bowel disease (IBD) patients. There is no standardized approach for PG treatment.

Identifiants

DOI: 10.1016/j.cgh.2018.10.047 PMID: 30404036
pubmed: 30404036
pii: S1542-3565(18)31214-X
doi: 10.1016/j.cgh.2018.10.047
pii:
doi:

Substances chimiques

Immunologic Factors 0
Piperidines 0
Protein Kinase Inhibitors 0
Pyrimidines 0
Pyrroles 0
tofacitinib 87LA6FU830

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

991-993

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Auteurs

Bharati Kochar (B)

Multidisciplinary Center for Inflammatory Bowel Disease, University of North Carolina, Chapel Hill, North Carolina; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.

Neel Herfarth (N)

Division of Gastroenterology and Hepatology, University Hospital and University of Zurich, Zurich, Switzerland.

Céline Mamie (C)

Division of Gastroenterology and Hepatology, University Hospital and University of Zurich, Zurich, Switzerland.

Alexander A Navarini (AA)

Department of Dermatology, University Hospital and University of Zurich, Zurich, Switzerland.

Michael Scharl (M)

Division of Gastroenterology and Hepatology, University Hospital and University of Zurich, Zurich, Switzerland.

Hans H Herfarth (HH)

Multidisciplinary Center for Inflammatory Bowel Disease, University of North Carolina, Chapel Hill, North Carolina; Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina. Electronic address: hherf@med.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Disciplines des sciences naturelles › Chimie › Biochimie › Histocytochimie › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Disciplines des sciences naturelles › Chimie › Biochimie › Immunohistochimie › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Pipéridines › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Ulcère cutané › Pyodermie phadégénique › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrroles › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Système tégumentaire › Peau › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Tofacitinib for the Treatment of Pyoderma Gangrenosum.
Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › Jeune adulte › Tofacitinib for the Treatment of Pyoderma Gangrenosum.